• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: Terumo BCT Spectra Optia; SPECTRA OPTIA EXCHANGE SET

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

Terumo BCT Spectra Optia; SPECTRA OPTIA EXCHANGE SET Back to Search Results
Catalog Number 4122201
Medical Device Problem Code Insufficient Device Problem Information (3190)
Health Effect - Clinical Codes Hypersensitivity/Allergic reaction (1907); Low Blood Pressure/ Hypotension (1914); Thrombosis/Thrombus (4440)
Date of Event 12/28/2025
Type of Reportable Event Serious Injury
Event or Problem Description
Per journal article "peripheral venous access for low-volume centrifugal plasma exchange to treat patients with liver disorders" by janeela, a.M., chellaiya, g.K., thomas, r., bansal, a., kumar, s., sunderraj, g., jayaraman, s., kumar, s.E., alexander, v., david, v.G., varughese, s., daniel, d., nair, s.C., eapen, c.E., goel, a., & zachariah, u.G.Background/aims: centrifugal plasma exchange (plex), by virtue of low blood flow rates, can be performed via peripheral venous access.This study aims to assess the utilization, safety, and efficiency of low-volume centrifugal plasma exchange via peripheral venous access (p-plex)in liver disease patients.Methods: this retrospective cohort study compared patients with liver disease who underwent low-volume centrifugal p-plex (2019¿2024) with syndrome-matched patients who underwent plasma exchange via central venous access (c-plex).Data on plex procedure, venous access, and extraction efficiency for molecules of interest were noted.Results: of 448 liver disease patients who underwent centrifugal low-volume plex, 81 patients (18.1%) who underwent p-plex (m: 60; age: 37 "[29.5¿46.5]" years; median, interquartile range) were compared with 81 syndrome-matched patients who underwent c-plex (m: 62; age: 37 "[29.5¿46.5]" years; acute-on-chronic liver failure: 44, acute liver injury/acute liver failure: 21, others: 20).Targeted p-plex sessions were completed in 67 of 81 (82%).P-plex access was mostly 18-g (n = 64/72 for inlet/return)in antecubitalfossa.Thirteen of 81 (16%) p-plex patients required access change to cplex.Procedure time was longer in p-plex group (105 "[82.5¿120]" min) than in the c-plex group (75 "[60¿91.3]" min, p value< 0.001) due to lower flow rates in p-plex.When controlled for exchange volumes and baseline values, extraction efficiency of bilirubin (p-plex: 34.3% "[21.2¿42.6]", c-plex: 27.1% "[10.3¿41.7]"; p value: 0.14) and von willebrand factor antigen (p-plex: 36.1% "[21.8¿46.8]", c-plex: 45.6% "[32.8¿58.3]"; p value: 0.19) were similar in both groups.Plex was performed in the ward (in high monitoring area) in majority of patients in the p-plex group (73 "[90.1%]") and in the high-dependency unit (43 "[53.1%]") in the c-plex group.Lower linerelated complications with p-plex (2/81) vis-a-vis c-plex (9/81, p-value: 0.03) were noted.Conclusion: in this report, low-volume centrifugal plex to treat liver disease was performed via peripheral venous access in 18% of patients.P-plex was done in the ward, with similar efficiency and better line-related safety; however, the plex duration was prolonged by 30 min.Specific details, such as patient information and outcome, were not included in the article for these events, therefore this report is being provided as a summary of the events.It is unknown at this time if medical intervention was required for these events this report is being filed due to patient death, although per current information there is no detectable malfunction with the terumo bct device or allegation of a malfunction.The collection set is not available for return because it was discarded by the customer.
 
Additional Manufacturer Narrative
Investigation is in process, a follow-up report will be provided.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
Spectra Optia
Common Device Name
SPECTRA OPTIA EXCHANGE SET
Manufacturer (Section D)
Terumo BCT
lakewood CO 80215
Manufacturer (Section G)
Terumo BCT
10810 w. collins ave
lakewood CO 80215
Manufacturer Contact
kristi edgington
10810 w. collins ave
lakewood, CO 80215
MDR Report Key25843289
Report Number1722028-2026-00105
Device Sequence Number21392840
Product Code LKN
UDI-Device Identifier05020583122208
UDI-Public05020583122208
Combination Product (Y/N)N
Initial Reporter CountryIN
PMA/510(K) Number
K183081
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source Foreign,Literature
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 07/16/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Catalogue Number4122201
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 06/23/2026
Supplement Date Received by Manufacturer09/25/2026
Initial Report FDA Received Date07/16/2026
Supplement Report FDA Received Date09/25/2026
Was Device Evaluated by Manufacturer? (Y/N) No
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Other;
Patient SexUnknown
-
-